
A study assessed sacubitril valsartan's impact on heart failure (HF) in hemodialysis patients with preserved ejection fraction (HFpEF). Over 12 months, 155 patients, with EF >40%, were monitored, 59 receiving SV. SV improved diastolic function and reduced left ventricular parameters but didn't significantly alter HF hospitalization or cardiovascular death rates. The Acute Dialysis Quality Initiative (ADQI) HF class improved with SV. Independent risk factors for HFpEF patients included age, diabetes, and pulmonary arterial pressure. While SV enhanced certain cardiac measures, it didn't reduce HF hospitalization or cardiovascular mortality in this population.
Like
Save
Share